US · MYGN
Myriad Genetics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Salt Lake City, UT 84108
- Website
- myriad.com
Price · as of 2025-12-31
$4.80
Market cap 429.72M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36.95 | +669.79% |
| Intrinsic Value(DCF) | $2.00 | -58.33% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $11.30 | $20.70 | |||
| 2012 | $13.47 | $40.45 | |||
| 2013 | $17.39 | $55.81 | |||
| 2014 | $18.90 | $79.02 | |||
| 2015 | $12.43 | $1.61 | |||
| 2016 | $16.85 | $21.75 | |||
| 2017 | $8.36 | $3.33 | |||
| 2018 | $18.75 | $15.71 | |||
| 2019 | $9.45 | $1.12 | |||
| 2020 | $0.00 | $42.38 | |||
| 2021 | $26.12 | $55.50 | $0.17 | $7.62 | $0.00 |
| 2022 | $21.23 | $125.67 | $0.00 | $0.48 | $0.00 |
| 2023 | $22.61 | $27.67 | $0.00 | $0.00 | $0.00 |
| 2024 | $10.18 | $32.85 | $0.00 | $0.00 | $0.00 |
| 2025 | $5.01 | $36.95 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Myriad Genetics, Inc.'s (MYGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36.95
- Current price
- $4.80
- AI upside
- +669.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.00
-58.33% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MYGN | Myriad Genetics, Inc. | $4.80 | 429.72M | +670% | -58% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| AMN | AMN Healthcare Services, … | $19.48 | 748.3M | +170% | -58% | — | — | — | 1.22 | 0.29 | 15.68 | — | -1.98 | 22.93% | 1.21% | -3.51% | 0.00% | 1.94% | 0.00% | 1.30 | 0.73 | 0.94 | 0.72 | 7.90 | -3558.00% | -849.00% | 1250.00% | 34.29% | 0.47 | 16.66% | 0.00% | — | 36.62% | 47.79 | 5.88 | 0.58 | 2.47 |
| CDNA | CareDx, Inc | $18.76 | 964.88M | +90% | -24% | -84% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| CSTL | Castle Biosciences, Inc. | $29.57 | 863.11M | +72% | -30% | -71% | — | -33.58 | 1.72 | 2.36 | 48.38 | — | 2.19 | 68.66% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -23387.00% | 366.00% | -2248.00% | 3.49% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -12.82 | 19.37 | 1.59 | 4.94 |
| DNA | Ginkgo Bioworks Holdings,… | $6.75 | 408.98M | +75% | -49% | — | +1,219% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| EVH | Evolent Health, Inc. | $3.25 | 376.91M | +378% | -56% | — | +2,393% | -0.71 | 0.98 | 0.22 | -0.76 | -0.13 | -0.47 | 15.09% | -0.24% | -28.49% | -81.81% | -0.48% | -26.08% | 0.05 | -0.08 | 1.31 | 1.23 | 0.37 | 52593.00% | -2656.00% | -17759.00% | 1.16% | 0.10 | 0.52% | 2.72% | -1.90% | 194.02% | -62.28 | 58.08 | 0.15 | 0.25 |
| FLGT | Fulgent Genetics, Inc. | $15.33 | 473.89M | +1,814% | -46% | +66% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
- CEO
- Samraat S. Raha
- Employees
- 2.7K
- Beta
- 1.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.00 ÷ $4.80) − 1 = -58.33% (DCF, example).